US biotech Jazz Pharmaceuticals (Nasdaq: JAZZ) is banking on continued growth from Epidiolex (cannabidiol), the first plant-derived CBD medicine approved by the US regulator to treat seizures linked to rare epilepsies.
The drug pulled in nearly $1 billion in sales last year, and analysts at DelveInsight, which has authored a report on the company’s improving prospects, expect the trend to hold.
Epidiolex is used to treat Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in patients aged one and up. It remains the only FDA-approved prescription cannabidiol on the market, a status that underscores its position in a fast-moving but still uneven therapeutic category.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze